Effective protection against PRRSV NADC30 by recombinant chimpanzee adenovirus vaccines expressing GP35 or M-GP5 fusion proteins.
Two recombinant chimpanzee adenovirus vaccine candidates were constructed to express the GP35 or M-GP5 fusion proteins of the PRRSV NADC30-like strain, resulting in a potent antigen-specific immune response, including enhanced GP5-specific antibody production, neutralizing activity, and T-cell-mediated immunity.